Larvol Delta - Safety-Dose-Tolerance-Pharmacokinetics-Pharmacodynamics-of-CPXPOM-in-Patients-With-Newly-Diagnosed-or-Recurrent-Bladder-Tumors

fosciclopirox (CPX-POM) - BioNOVUS, University of Kansas Medical Center

http://clinicaltrials.gov/ct2/show/NCT04525131

Aug 25, 2020

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next